Fundz

Transcode Therapeutics Announces Equity Investment From White Lion Capital To Help Fund Development Of Ttx-Mc138 For Treatment Of Glioblastomas

PUBLIC · RNAZApr 14, 2023

Round Type

Venture

BostonBiotechnologyHealth CareMedicalTherapeutics

Description

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology CompanyTM committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a Common Stock Purchase Agreement (the “Agreement”) with White Lion Capital, LLC (“White Lion Capital”) an investor in the glioblastomas / oncology sector. The Agreement provides the Company with the right to sell White Lion Capital up to approximately $1.08 million of its common stock until May 31, 2023, subject to certain limitations and conditions. The Company intends to use the net proceeds from the transaction for working capital and general corporate purposes.

Quick answer

TransCode Therapeutics raised an undisclosed amount in a funding round, dated April 14, 2023. TransCode Therapeutics is based in Boston, Massachusetts, United States.

How much did TransCode Therapeutics raise?
TransCode Therapeutics raised an undisclosed amount in a funding round on April 14, 2023.
What does TransCode Therapeutics do?
TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.
Where is TransCode Therapeutics based and how big is it?
TransCode Therapeutics is based in Boston, Massachusetts, United States. Fundz records about 7 employees.
Who are the decision-makers at TransCode Therapeutics?
Fundz holds 2 contacts at TransCode Therapeutics, including the Chief Technology Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as TransCode Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Qnovia raised $2.9M on May 25, 2023.
  • Renibus Therapeutics raised $64M on May 25, 2023.
  • Decoy Therapeutics Inc. raised $6M on May 11, 2023.
  • OncoLize raised $1.7M (Seed) on April 13, 2023.
  • Conformal Medical raised $35M on May 26, 2023.
  • Patient21 raised $108M (Funding Round) on May 22, 2023.

Who to call at TransCode Therapeutics, and when

A new round usually means TransCode Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day TransCode Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at TransCode Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TransCode Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TransCode Therapeutics

Location

Boston, Massachusetts, United States

About

TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its proprietary iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. Another of the company’s drug candidates, TTX-siPDL1, focuses on treating tumors by targeting a protein called Programmed death-ligand 1 (PD-L1). TransCode also has three cancer-agnostic programs: TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I designed to drive an immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TransCode Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsZdravka M., Chief Technology Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for TransCode Therapeutics's next move

See what Strategic adds

TransCode Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.